7 completed. 7 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 7 |
| Phase 2 | 2 | Completed 2 |
Follow Vaso-Occlusive Crises: new trials by email Literature Review of Vaso-Occlusive Crises trials Research Report on Vaso-Occlusive Crises
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interest of Famotidine in Children With Sickle Cell Disease Famotidine 400 mg/50 mL - Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2022-01-12 | 2025-10-08 |
| A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Completed | Pfizer | 241 | 2021-10-04 | 2025-12-02 |
| Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia Omega 3, Vit D, Zinc sulfate - Vaso-occlusive Crisis, Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Beni-Suef University | 350 | 2019-11-01 | 2021-01-27 |
| Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease Rivipansel, Placebo - Anemia, Sickle Cell | Phase 3 | Completed | Biossil Inc. | 345 | 2015-06-17 | 2025-03-11 |
| Evaluation of Repeat Administration of Purified Poloxamer 188 MST-188 - Sickle Cell Disease | Phase 3 | Completed | Mast Therapeutics, Inc. | 16 | 2015-06-01 | 2016-10-28 |
| Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) Saline, MST-188 - Vaso-occlusive Crisis, Sickle Cell Disease | Phase 3 | Completed | Mast Therapeutics, Inc. | 388 | 2013-05-01 | 2016-10-28 |
| A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia L-glutamine, Placebo - Sickle Cell Anemia, Sickle ß0-Thalassemia | Phase 3 | Completed | Emmaus Medical, Inc. | 230 | 2010-05-01 | 2020-08-19 |
Anemia, Sickle Cell (7) · Hematologic Diseases (1) · Sickle Cell Trait (1)
Anemia (7) · Anemia, Hemolytic (7) · Anemia, Hemolytic, Congenital (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Hemic and Lymphatic Diseases (7) · Hemoglobinopathies (7) · Hematologic Diseases (6)
Cardiovascular Agents (1) · Docosahexaenoic Acids (1) · Famotidine (1) · Glutamine (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Hydroxyurea (1) · Morphine (1) · Simvastatin (1) · Sodium Chloride (1) · Zinc Sulfate (1) · inclacumab (1) · maltodextrin (1) · rivipansel (1)
Mast Therapeutics, Inc. (2) · Assistance Publique - Hôpitaux de Paris (1) · Beni-Suef University (1) · Biossil Inc. (1) · Emmaus Medical, Inc. (1) · Pfizer (1)
United States (5) · Brazil (2) · Egypt (2) · France (2) · Lebanon (2) · Oman (2) · Saudi Arabia (2) · Turkey (Türkiye) (2) · Belgium (1) · Canada (1) · Colombia (1) · Dominican Republic (1) · Jamaica (1) · Jordan (1) · Kenya (1)
Ahmed F Mahmoud Hussein, MS.c (1) · Edwin L Parsley, D. O. (1) · Edwin L. Parsley, D.O. (1) · Yutaka Niihara, MD, MPH (1)
PMID 30021096, PMID 33877274, PMID 35120836, PMID 35981565, PMID 37722599, PMID 38775255